Aridis Financial Statements From 2010 to 2024
| ARDSDelisted Stock | USD 0.27 0.02 8.00% |
Check Aridis Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aridis main balance sheet or income statement drivers, such as , as well as many exotic indicators such as . Aridis financial statements analysis is a perfect complement when working with Aridis Pharmaceuticals Valuation or Volatility modules.
Aridis |
Aridis Pharmaceuticals Company Shares Owned By Insiders Analysis
Aridis Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Aridis Pharmaceuticals Shares Owned By Insiders | 31.53 % |
Most of Aridis Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aridis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
CompetitionBased on the latest financial disclosure, 31.53% of Aridis Pharmaceuticals are shares owned by insiders. This is 107.71% higher than that of the Biotechnology sector and 122.36% higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is notably lower than that of the firm.
Aridis Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Aridis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Aridis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Aridis Pharmaceuticals competition to find correlations between indicators driving Aridis Pharmaceuticals's intrinsic value. More Info.Aridis Pharmaceuticals is rated below average in return on asset category among related companies. It is rated second in operating margin category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Aridis Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Aridis Pharmaceuticals' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Aridis Pharmaceuticals' earnings, one of the primary drivers of an investment's value.About Aridis Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Aridis Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Aridis Pharmaceuticals investors use historical funamental indicators, such as Aridis Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Aridis Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Aridis Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Aridis Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Aridis Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Aridis Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies to treat life-threatening infections. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California. Aridis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 34 people.
Pair Trading with Aridis Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aridis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aridis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Aridis Pink Sheet
| 0.64 | YS | YS Biopharma | PairCorr |
Moving against Aridis Pink Sheet
| 0.67 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.64 | DRMA | Dermata Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.62 | DRTS | Alpha Tau Medical Financial Report 28th of May 2024 | PairCorr |
| 0.61 | VCYT | Veracyte Financial Report 2nd of May 2024 | PairCorr |
| 0.6 | KA | Kineta Inc Financial Report 9th of May 2024 | PairCorr |
The ability to find closely correlated positions to Aridis Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aridis Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aridis Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aridis Pharmaceuticals to buy it.
The correlation of Aridis Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aridis Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aridis Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aridis Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Aridis Pharmaceuticals information on this page should be used as a complementary analysis to other Aridis Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |